Relapsing remitting multiple sclerosis in patients under treatment with laquinimod

Vera Kolyovska; Dimitar Maslarov

首页> 外文期刊>Acta morphologica et anthropologica >Relapsing remitting multiple sclerosis in patients under treatment with laquinimod

【24h】

Relapsing remitting multiple sclerosis in patients under treatment with laquinimod

机译：

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS), which is pathophysiologically characterized by both inflammatory demyelination and neurodegeneration. Laquinimod is a small molecule, an investigation for oral drug administration being developed for the treatment of relapsing-remitting multiple sclerosis (RRMS). We explore serum IgG antibodies to GM1, GM3 and GD1a gangliosides in our patients under laquinimod treatment. The results show high IgG titers of anti-GM1 antibodies, but low titers of anti-GM3 and anti-GD1a antibodies. There are no data laquinimod to affect the demyelinisation - in almost all patients the anti-GM1 antibodies titer is positive. It can be concluded that laquinimod has a neuroprotective action. Oral application of laquinimod against MS may reduce brain damage caused by neurodegeneration. Laquinimod has dual properties of immunomodulation and neuroprotection, and is a potentially promising oral treatment of RRMS.

著录项

来源
《Acta morphologica et anthropologica》 |2019年第4期|56-61|共6页
作者
Vera Kolyovska; Dimitar Maslarov;
展开▼
作者单位

Institute of Experimental Morphology, Pathology and Anthropology with Museum, BAS, Sofia, Bulgaria;

Medical University of Sofia, Neurology Clinic of First MHAT "St. John the Baptist", Sofia, Bulgaria;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类细胞生物学;
关键词
serum anti-ganglioside antibodies; laquinimod; relapsing-remitting multiple sclerosis; neuronal damage; neuroprotection;

Relapsing remitting multiple sclerosis in patients under treatment with laquinimod

摘要

著录项

相关主题

期刊订阅